Tajikistan Four Liability Pathways for Harm Compensation: Article 47 Analysis

1. Key takeaways

Article 47 divides product harm compensation liability in Tajikistan into four independent pathways by cause of harm, each with a different subject of liability: under paragraph 1 liability falls on the manufacturer (where the product was used as intended but harm resulted from its defective manufacture, or where harm resulted from false information in the instructions for use published by the manufacturer); under paragraph 2 liability falls on the entities carrying out wholesale and retail (where violation of the rules on storage, transport, wholesale and retail caused product deterioration and harm); under paragraph 3 liability falls on medical institutions or medical workers (where harm resulted from incorrect or unjustified prescription); under paragraph 4 liability falls on the violator of the destruction rules (including environmental damage). GRZAN points out that paragraph 1 expressly applies to medical products: both scenarios in the provision name medical products in parallel, making this the article with the most direct binding force on devices.

2. Legal basis

3. Expert insights

Insight 1: the two scenarios in Article 47(1) correspond to two completely different evidentiary structures. Scenario (1) requires proof of both use as intended in accordance with the instructions and defective manufacture of the product; scenario (2) requires only proof that harm resulted from false information in the instructions. For device companies, the evidentiary threshold of scenario (2) is lower — falsity of the instructions themselves is sufficient, without first proving a manufacturing defect. GRZAN recommends making the localized review of instructions for use an independent quality control node.

Insight 2: Article 1 defines instructions for use as a document approved under the procedure of the Ministry of Health, closing the loop with Article 47(1)(2). Once approved, the instructions acquire the character of an official document, and the accuracy of their content directly determines whether compensation liability arises. False instructions are no longer merely an administrative violation; they are an independent ground for damage compensation.

Insight 3: Article 47(2) and Article 47(3) provide manufacturers with two channels of liability isolation. If the harm resulted from violations at the storage and transport stage, liability shifts to the wholesale and retail entities; if it resulted from unjustified prescription, liability shifts to the medical institution or medical worker. When responding to claims, manufacturers must first secure the storage and transport records and the usage records to show that the harm falls outside the coverage of paragraph 1.

Insight 4: Article 47(4) includes environmental damage within the scope of compensation. The objects of harm under this paragraph are human health and the environment, a formulation that is relatively distinctive among similar provisions in the Central Asia market. When entrusting local destruction institutions, companies must verify their disposal qualifications and compliance.

Insight 5: Article 47(5) and Article 48 form a double safety net. Paragraph 5 confirms that compensation is implemented under the legislation of the Republic of Tajikistan, while Article 48 covers all liability for failure to comply with the requirements of the law. Beyond the four pathways, general liability provisions still apply.

4. Practical recommendations

1. Make the localized review of instructions for use an independent quality control node. Under Article 47(1)(2) and Article 1(21), false content in the instructions constitutes an independent ground for compensation.
2. Build an evidence retention system across the whole life cycle. Under Article 47(1), (2) and (3), retain production and testing records, storage and transport temperature records and clinical usage records, so as to support proof and allocation of liability in claims.
3. Implement storage and transport rules and liability transfer in distribution agreements. Under Article 47(2), define the storage and transport standards at the wholesale and retail stages and the attribution of liability for violations.
4. Verify the qualifications of local destruction institutions. Under Article 47(4), the scope of compensation for destruction violations includes environmental damage, so the compliance qualifications of disposal institutions must be checked.
5. Include Article 48 in the overall compliance risk assessment. Under Article 48, conduct outside the four pathways is still subject to liability under the legislation.

5. Verification checklist

• □ Confirmed the four liability pathways of Article 47 and the subject of liability of each
• □ Confirmed that both scenarios of Article 47(1) name medical products in parallel
• □ Confirmed that Article 1(21) defines instructions for use as a document approved under the procedure of the Ministry of Health
• □ Made the localized review of instructions for use an independent quality control node
• □ Established a retention mechanism for production and testing, storage and transport temperature, and clinical usage records
• □ Implemented storage and transport rules and liability transfer in distribution agreements
• □ Verified the qualifications of local destruction institutions (Article 47(4) includes environmental damage)
• □ Included Article 48 in the overall compliance risk assessment

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com